What's in B. Braun Melsungen AG's pipeline?

B. Braun Melsungen AG has 25 drugs in our index: 13 marketed, 0 filed, 11 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with B. Braun Melsungen AG's portfolio?

Top competitors by shared drug class: Amsterdam UMC, location VUmc, B. Braun Medical SA, Baxalta now part of Shire, Fujian Shengdi Pharmaceutical Co., Ltd., General University Hospital, Prague.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/b-braun-melsungen-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

B. Braun Melsungen AG — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

B. Braun Melsungen AG pipeline: 13 marketed, 0 filed, 11 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

13 marketed 0 filed 11 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Lipidem	Lipidem	marketed			Metabolic
HES 6%	HES 6%	marketed
Lipoplus 20%	Lipoplus 20%	marketed	Lipid emulsion for parenteral nutrition		Nutrition support / Critical care
balanced electrolyte solution	balanced electrolyte solution	marketed
Lipofundin MCT	Lipofundin MCT	marketed	Lipid emulsion for parenteral nutrition		Nutrition support
Lipofundin N 20%	Lipofundin N 20%	marketed	Lipid emulsion; parenteral nutrition component		Nutrition support; Critical care
Balanced gelatine solution	Balanced gelatine solution	marketed	Colloid plasma substitute		Critical Care / Anesthesia
Lipofundin MCT 20%	Lipofundin MCT 20%	marketed	Lipid emulsion; parenteral nutrition supplement		Nutrition support; Critical care
Propofol 1%	Propofol 1%	marketed	Intravenous anesthetic	GABA-A receptor	Anesthesiology
Lipoplus	Lipoplus	marketed			Other
HES 10%	HES 10%	marketed	Synthetic colloid plasma volume expander		Critical Care / Anesthesia
Albumin + electrolyte solution	Albumin + electrolyte solution	marketed	Colloid solution / Plasma expander		Critical Care / Fluid Resuscitation

Therapeutic area mix

Critical Care / Anesthesia · 3
Nutrition support / Critical care · 2
Nutrition support; Critical care · 2
Anesthesiology · 2
Critical Care; Hematology · 1
Critical Care; Perioperative Medicine · 1
Immunology · 1
Metabolic · 1
Nutrition Support / Critical Care · 1
Nutrition support · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amsterdam UMC, location VUmc · 1 shared drug class
B. Braun Medical SA · 1 shared drug class
Baxalta now part of Shire · 1 shared drug class
Fujian Shengdi Pharmaceutical Co., Ltd. · 1 shared drug class
General University Hospital, Prague · 1 shared drug class
Impax Laboratories, LLC · 1 shared drug class
Medical University of Vienna · 1 shared drug class
Nanjing Chia-tai Tianqing Pharmaceutical · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for B. Braun Melsungen AG:

Cite this brief

Drug Landscape (2026). B. Braun Melsungen AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/b-braun-melsungen-ag. Accessed 2026-05-16.